Alexander Disease
Why in News?
Alexander Disease is in the news because on September 3, 2026, U.S. Food and Drug Administration (FDA) approved Zanvastro (zilganersen), the first-ever drug to treat this rare and progressive neurological disorder.
About
- Definition: It is an extremely rare, progressive, and potentially life-threatening leukodystrophy (a group of disorders that destroy the brain's white matter).
- Astrocyte Disorder: It stands out as the only known genetic disorder specifically affecting astrocytes—the star-shaped helper cells that support and nourish the central nervous system.
- Rarity: It impacts fewer than 1 in a million people worldwide.
Causes and Mechanisms
- GFAP Gene Mutation: Most cases are driven by a sporadic, non-inherited mutation in the GFAP gene on chromosome 17.
- Protein Toxic Buildup: The mutation forces the body to produce too much Glial Fibrillary Acidic Protein (GFAP). Instead of helping, the excess protein aggregates into toxic, rod-like structures called Rosenthal fibers.
- Myelin Destruction: These toxic deposits cause astrocytes to malfunction, destroying the myelin sheath (the protective coating around nerve fibers) and cutting off brain signals.
Subtypes and Age-Specific Symptoms
The disease spans across all life stages, but early-onset cases are typically the most severe:
The disease spans across all life stages, but early-onset cases are typically the most severe:
- Neonatal Form (First Month): Causes severe seizures, hydrocephalus (fluid accumulation in the brain), and profound intellectual disabilities.
- Infantile Form (Under Age 2): The most common form. Symptoms include megalencephaly (abnormally enlarged brain and head size), developmental delays, seizures, and severe muscle stiffness (spasticity).
- Juvenile Form (Ages 2–13): Characterized by speech difficulties, frequent vomiting, coordination problems, and trouble swallowing.
- Adult Form: The rarest and most variable presentation. It develops slowly and may mimic multiple sclerosis or manifest primarily through chronic vomiting or sleep/eye movement issues.
Diagnosis and Treatment
- Diagnosis: Doctors initially suspect the condition via MRI scans (which show distinct damage localized to the frontal white matter) and confirm it through genetic testing.
- Targeted Therapy: Zanvastro (zilganersen) is administered intrathecally (into the spinal canal) to slow or halt further damage by shutting down overactive GFAP production. It cannot, however, repair myelin that has already been destroyed.
- Supportive Care: Traditional therapies remain vital, such as anti-seizure medications, physical therapy for muscle tone, and nutritional support for swallowing issues.
